133804-44-1
![133804-44-1 结构式](https://img.chemicalbook.com/CAS/GIF/133804-44-1.gif)
133804-44-1 性质
密度 | 1.302±0.06 g/cm3(Predicted) |
---|---|
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
形态 | 固体 |
酸度系数(pKa) | -1.76±0.42(Predicted) |
颜色 | 白色至浅黄色 |
133804-44-1 用途与合成方法
Na + /Ca 2+ exchanger
Caldaret (MCC-135) is demonstrated to restore Ca 2+ -ATPase activity of the sarcoplasmic reticulum (SR) isolated from the myocardium acutely exposed to ischemia and reperfusion in vitro.
Caldaret, an intracellular Ca 2+ handling modulator, limits infarct size of reperfused canine heart. The cardioprotective effect of Caldaret, a novel intracellular Ca 2+ handling modulator that acts through reverse-mode Na + /Ca 2+ exchanger inhibition and potential sarcoplasmic reticulum (SR) Ca 2+ uptake enhancement, against reperfusion injury is investigated. Intravenously infused Caldaret (3 or 30 microg/kg per hour) for 30 min at left circumflex (LCX)-reperfusion markedly reduces infarct size (by 51.3% or 71.9%, respectively). The amelioration of intracellular Ca 2+ handling dysfunction achieved by Caldaret leads to cardioprotective effects against reperfusion injury following prolonged ischemia. Caldaret (MCC-135) is a new potent compound with beneficial effects in heart failure. In diabetic rats, Caldaret decreases TR80 significantly without significant effect on developed tension (DT). Caldaret has minimal effects on SR Ca 2+ uptake in normal rats, that is observed as increased SR Ca 2+ uptake at uptake time of 20 and 30 s at the highest concentration of 10 μM. In diabetic rats, Caldaret increases SR Ca 2+ uptake all over the range of uptake time. Both initial rate of SR Ca 2+ uptake and the amount of Ca 2+ accumulated in the SR with longer uptake time are increased by Caldaret.
133804-44-1 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-04-30 | HY-100298 | 133804-44-1 | 133804-44-1 | 5 mg | 6140 |
2024-04-30 | HY-100298 | 133804-44-1 | 133804-44-1 | 10 mg | 8600 |